arrow
B

Beatrice Casadei

aou san giovanni battista-molinette
H指数:21
被引数:1,695

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes of CAR T-Cell Therapy in Transformed Indolent Non-Hodgkin Lymphomas and de novo DLBCL: a comparative analysis from the Italian CAR T-SIE study

CAR T细胞疗法在转化型惰性非霍奇金淋巴瘤和原发型DLBCL中的疗效:来自意大利CAR T-SIE研究的比较分析

2026-06-130
PRE
Polatuzumab vedotin–containing regimens as bridge to CART: analysis from the CART-SIE study

Polatuzumab vedotin-含方案作为桥接CART:CART-SIE研究分析

2026-05-070
OA
A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma

真实世界多中心研究:检查点抑制剂在复发/难治性原发纵隔B细胞淋巴瘤中的应用

2026-04-100
PRE
Systemic inflammation and CAR-T specific toxicities as major drivers of non-relapse mortality: analysis from the Italian prospective observational CART-SIE Study

系统性炎症和CAR-T特异性毒性作为非复发死亡率的主要驱动因素:来自意大利前瞻性观察性CART-SIE研究的分析

2026-02-230
OAAI
Risk Factors for Persisting SARS-CoV-2 Infection in Patients with B-Cell Malignancies in the Omicron Era: A Multicenter Cohort Study

奥密克戎时代B细胞恶性肿瘤患者持续性SARS-CoV-2感染的危险因素:一项多中心队列研究

2025-09-080
OAAI
Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis

CAR T细胞疗法在高等级B细胞淋巴瘤中的疗效与弥漫大B细胞淋巴瘤的比较:一项加权比较分析

2025-08-070
OAAI
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice
2025-03-010
OAAI
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study

CAR-hematox的前瞻性验证和简化版本预测Anti-CD19 CAR T细胞治疗的大b细胞淋巴瘤患者的生存: 来自cart-sie研究的数据

2025-01-010
OAAI
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
2024-11-070
OAAI
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
2024-07-020
OAAI
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells
2024-06-041
OAAI
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
LEUKEMIA
IF13.4
2024-03-084
OAAI